New GSK Spin-Out Targets Hearing Loss
This article was originally published in Start Up
Executive Summary
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.
You may also be interested in...
Autifony Tunes In To Jazz With Neurology-Focused Deal
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
GSK Spin-Out NeRRe Raises £23m For NK Antagonists
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.